APOPTOSISKITS - M30 APOPTOSENSE^® ELISA - ADDITIONAL BACKGROUND INFORMATION - HEPATOLOGY REFERENCES

download this page as a .pdf

Original Papers:

M30 Apoptosense® Assay:

Hägg M, Bivén K, Ueno T, Rydlander L, Björklund P, Wiman KG, Shoshan M, Linder S. (2002)
A novel high-through-put assay for screening of pro-apoptotic drugs.
Invest New Drugs. 2002 Aug;20(3):253-9.

M30-Antibody:

 Leers MP, Kölgen W, Björklund V, Bergman T, Tribbick G, Persson B, Björklund P, Ramaekers FC, Björklund B, Nap M, Jörnvall H, Schutte B. (1999)
Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis.
J Pathol. 1999 Apr;187(5):567-72.

2010

Yilmaz Y, Kurt R, Kalayci C.
Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments.
Biomark Med. 2010 Oct;4(5):743-5.

Adams LA, Feldstein AE.
Non-invasive Diagnosis of Nonalcoholic Fatty Liver and Nonalcoholic Steatohepatitis.
J Dig Dis. 2010 Nov 17. [Epub ahead of print]

Adams LA, Feldstein AE.
Nonalcoholic steatohepatitis: risk factors and diagnosis.
Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):623-35.

Tarek I. Abu-Rajab Tamimia, Hesham M. Elgouharib, Naim Alkhouric, Lisa M. Yeriand, Michael P. Berke, Rocio Lopezf, Phillip R. Schauerg, Nizar N. Zeina and Ariel E. Feldstein
An Apoptosis Panel for Nonalcoholic Steatohepatitis Diagnosis
Article in Press. Available online 22 October 2010.

Anty R, Iannelli A, Patouraux S, Bonnafous S, Lavallard VJ, Senni-Buratti M, Ben Amor I, Staccini-Myx A, Saint-Paul MC, Berthier F, Huet PM, Le Marchand-Brustel Y, Gugenheim J, Gual P, Tran A.
A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients.
Aliment Pharmacol Ther. 2010 Dec;32(11-12):1315-1322.

Musso G, Gambino R, Cassader M, Pagano G.
Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.
Ann Med. 2010 Nov 2. [Epub ahead of print]

Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C.
Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis.
World J Gastroenterol. 2010 Oct 14;16(38): 4784-91.

Feldstein AE, Nobili V.
Biomarkers in nonalcoholic fatty liver disease: a new era in diagnosis and staging of disease in children.
J Pediatr Gastroenterol Nutr. 2010 Oct;51(4):378-9.

Samuel D, Ichai P.
Prognosis indicator in acute liver failure: Is there a place for cell death markers?
J Hepatol. 2010 Oct;53(4):593-5.

Bechmann LP, Jochum C, Kocabayoglu P, Sowa JP, Kassalik M, Gieseler RK, Saner F, Paul A, Trautwein C, Gerken G, Canbay A.(2010)
Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury.
J Hepatol. 2010 Oct;53(4):639-47.

Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, Debruyne R, Dhawan A.
Serum Levels of CK18 M30 and Leptin Are Useful Predictors of Steatohepatitis and Fibrosis in Paediatric NAFLD.
J Pediatr Gastroenterol Nutr. 2010 Aug 25. [Epub ahead of print]

Eren F, Yilmaz Y, Kose S, Ozdemir FT, Yonal O, Kurt R, Ozdogan O, Avsar E.
Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B.
Clin Chim Acta. 2010 Aug 28. [Epub ahead of print]

Antoine D, Williams D, Kipar A, Laverty H, Park B.
Diet restriction inhibits apoptosis, HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity.
Mol Med. 2010 Aug 27. [Epub ahead of print]

Gieseler RK, Marquitan G, Schlattjan M, Sowa JP, Bechmann LP, Timm J, Roggendorf M, Gerken G, Friedman SL, Canbay A.
Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C.
J Viral Hepat. 2010 Aug 15. [Epub ahead of print]

Dechêne A, Sowa JP, Gieseler RK, Jochum C, Bechmann LP, El Fouly A, Schlattjan M, Saner F, Baba HA, Paul A, Dries V, Odenthal M, Gerken G, Friedman SL, Canbay A. (2010)
Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation.
Hepatology. 2010 May 14. [Epub ahead of print]

Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. (2010)
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
Gut. 2010 Jul;59(7):969-74.

Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, Afendy A, Younoszai Z, Goodman Z, Baranova A. (2010)
A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis.
Obes Surg. 2010 Jun 8. [Epub ahead of print]

Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, Komatsu M,, Nagaya T, Joshita S, Yoshizawa K, Aoyama T, Tanaka E, Sano K. (2010)
Serum Fragmented Cytokeratin 18 Levels Reflect the Histologic Activity Score of Nonalcoholic Fatty Liver Disease More Accurately Than Serum Alanine Aminotransferase Levels.
J Clin Gastroenter. 2010 Jul;44(6):440-7.

Li X, Zhang Y, Wu K, Fan D. (2010)
Serum cytokeratin-18 fragment level: a noninvasive biomarker for not only nonalcoholic steatohepatitis, but also alcoholic steatohepatitis.
Hepatology. 2010 May;51(5):1865-6.

Valva P, De Matteo E, Galoppo MC, Gismondi MI , Preciado MV. (2010)
Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis.
J Med Virol. 2010 May;82(6):949-57.

Paschos KA, Charsou C, Constantinidis TC, Anagnostoulis S, Lambropoulou M, Papachristou F, Simopoulos K, Chatzaki E. (2010)
Corticotropin-releasing hormone receptors mediate opposing effects in cholestasis-induced liver cell apoptosis.
Endocrinology. 2010 Apr;151(4):1704-12.

Bechmann LP, Gieseler RK, Sowa JP, Kahraman A, Erhard J, Wedemeyer I, Emons B, Jochum C, Feldkamp T, Gerken G, Canbay A. (2010)
Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis.
Liver Int. 2010 Apr 9. [Epub ahead of print]

Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, Tiniakos DG, Margariti K, Archimandritis AJ. (2010)
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic fatty liver disease.
J Clin Gastroenter. 2010 Apr;44(4):e87-95.

Civera M, Urios A, Garcia-Torres ML, Ortega J, Martinez-Valls J, Cassinello N, Del Olmo JA, Ferrandez A, Rodrigo JM, Montoliu C. (2010)
Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity.
Diabetes Metab Res Rev. 2010 Mar;26(3):187-92.

Cave M, Falkner KC, Ray M, Joshi-Barve S, Brock G, Khan R, Bon Homme M, McClain CJ. (2010)
Toxicant-associated steatohepatitis in vinyl chloride workers.
Hepatology. 2010 Feb;51(2):474-81.   

Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, Wedemeyer I, Marquitan G, Gieseler RK, Baba HA, Gerken G, Canbay A. (2010)
Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis.
Hepatology. 2010 Jan;51(1):92-102.

Tan S, Bechmann LP, Benson S, Dietz T, Eichner S, Hahn S, Janssen OE, Lahner H, Gerken G, Mann K, Canbay A. (2010)
Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome.
J Clin Endocrinol Metab. 2010 Jan;95(1):343-8.

Sgier C, Müllhaupt B, Gerlach T, Moradpour D, Negro F, Malé PJ, Heim MH, Malinverni R, Cerny A, Dufour JF. (2010)
Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C.
J Viral Hepat. 2010 Jan 13. (Epub ahead of print)

2009

Bantel H, Schulze-Osthoff K. (2009)
Cell death in sepsis: a matter of how, when, and where.
Crit Care. 2009;13(4):173.

Feldstein A, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. (2009)
Cytokeratin-18 fragment levels as noninvasive biomarker for nonalcoholic steatohepatitis: A multicenter validation study.
Hepatology. 2009 Oct;50(4):1072-8.

Balmer ML, Siegrist K, Zimmermann A, Dufour JF. (2009)
Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis.
Liver Int. 2009 Sep;29(8):1184-8.

To the editor: Yilmaz Y (2009)
Defragmenting the noninvasive diagnosis of nonalcoholic steatohepatitis: Hopes from cytokeratin-18.
Hepatology. 2009 Sep;50(3):990-1.

To the editor: Bantel H, Bahr MJ, Schulze-Osthoff K. (2009)
An apoptosis biomarker for prediction of nonalcoholic steatohepatitis.
Hepatology. 2009 Sep;50(3):991.

Feldstein A, Kleiner D, Kravetz D, Buck M. (2009)
Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor.
J Clin Gastroenterol. 2009 Apr;43(4):374-81.

Hashimoto E, Farrell GC. (2009)
Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?
J Gastroenterol Hepatol. 2009 Apr;24(4):501-3.

Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N. (2009)
The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.
J Gastroenterol Hepatol. 2009 Apr;24(4):564-8.

Musso G, Gambino R, Pacini G, Pagano G, Durazzo M, Cassader M. (2009)
Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH.
Hepatology. 2009 Feb;49(2):426-35.

Musso G, Gambino R, Pacini G, De Michieli F, Cassader M. (2009)
Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver.
Am J Clin Nutr. 2009 Feb;89(2):558-67.

Hofer S, Brenner T, Bopp C, Steppan J, Lichtenstern C, Weitz J, Bruckner T, Martin E, Hoffmann U and Weigand. (2009)
Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction
Critical Care 2009, 13:R93.

Jochum C, Gieseler RK, Gawlista I, Fiedler A, Manka P, Saner FH, Roggendorf M, Gerken G, Canbay A. (2009)
Hepatitis B-associated Acute Liver Failure: Immediate Treatment with Entecavir Inhibits Hepatitis B Virus Replication and Potentially Its Sequelae
Digestion. 2009 Oct 15;80(4):235-240.

Yilmaz Y (2009)
Systematic review caspase-cleaved fragments of cytokeratin 18 – the promises and challenges of a biomarker for chronic liver disease
Aliment Pharmacol Ther. 2009 Dec 1;30(11-12):1103-9

Yilmaz Y, Kedrah AE, Ozdogan O. (2009)
Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis.
World J Gastroenterol. 2009 Sep 21;15(35):4387-91.

Wedemeyer I, Bechmann LP, Odenthal M, Jochum C, Marquitan G, Drebber U, Gerken G, Gieseler RK, Dienes HP, Canbay A. (2009)
Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C.
J Hepatol. 2009 Jan;50(1):140-9.

2008

Bechmann LP., Marquitan G, Jochum C, Saner F, Gerken G, Canbay A. (2008)
Apoptosis versus necrosis rate as a predictor in acute liver failure following acetaminophen intoxication compared with acute‑on‑chronic liver failure.
Liver International 2008 May;28(5):713‑6.

Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, Hazen SL, Feldstein AE. (2008)
Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients.
Clin Gastroenterol Hepatol. 2008 Nov;6(11):1249-54.

Papatheodoridis GV, Hadizyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, Manolakopoulos S, Tiniakos DG, Giannousis I, Manesis E, Archimandritis AJ. (2008)
Serum Apoptotic Caspase Activity As A Marker Of Severity In Hbeag‑Negative Chronic Hepatitis B Virus Infection.
Gut. 2008 Apr;57(4):500‑6.

Simopoulos C, Tsaroucha AK, Asimakopoulos B, Giatromanolaki A, Gavriilidis P, Polychronidis A, Karayiannakis A. (2008)
Total and caspase‑cleaved cytokeratin 18 in chronic cholecystitis: A prospective study.
BMC Gastroenterol. 2008 May 6;8(1):14.

Volkmann X, Anstaett M, Hadem J, Stiefel P, Bahr MJ, Lehner F, Manns MP, Schulze‑Osthoff K, Bantel H. (2008)
Caspase activation is associated with spontaneous recovery from acute liver failure.
Hepatology. 2008 May;47(5):1624‑33.

Vos MB, Barve S, Joshi-Barve S, Carew JD, Whitington PF, McClain CJ. (2008)
Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease.
J Pediatr Gastroenterol Nutr. 2008 Oct;47(4):481-5.

Wieckowska A, Feldstein AE. (2008)
Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive.
Semin Liver Dis. 2008 Nov;28(4):386-95.

Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. (2008)
A Novel Diagnostic Biomarker Panel for Obesity‑related Nonalcoholic Steatohepatitis (NASH).
Obes Surg. 2008 Nov;18(11):1430-7.

2007

Hetz H, Hoetzenecker K, Hacker S, Faybik P, Pollreisz A, Moser B, Roth G, Hoetzenecker W, Lichtenauer M, Klinger M, Krenn CG, Ankersmit HJ. (2007)
Caspase‑cleaved cytokeratin 18 and 20 S proteasome in liver degeneration.
J Clin Lab Anal. 2007;21(5):277‑81.

Mitry RR, De Bruyne R, Quaglia A, Hughes RD, Dhawan A. (2007)
Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers.
Hepatology. 2007 Dec;46(6):2047‑8.

Neuman MG, Benhamou JP, Marcellin P, Valla D, Malkiewicz IM, Katz GG, Trepo C, Bourliere M, Cameron RG, Cohen L, Morgan M, Schmilovitz‑Weiss H, Ben‑Ari Z. (2007)
Cytokine‑chemokine and apoptotic signatures in patients with hepatitis C.
Transl Res. 2007 Mar;149(3):126‑36.

Rutherford AE, Hynan LS, Borges CB, Forcione DG, Blackard JT, Lin W, Gorman AR, Shaikh OS, Reuben A, Harrison E, Reddy KR, Le WM, Chung RT; For the alf study group. (2007)
Serum Apoptosis Markers in Acute Liver Failure: A Pilot Study.
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1477-83.

Tumurbaatar B, Sun Y, Chan T, Sun J. (2007)
Cre‑estrogen receptor‑mediated hepatitis C virus structural protein expression in mice.
J Virol Methods. 2007 Dec;146(1‑2):5‑13. Epub 2007 Jul 12.

Wieckowska A, McCullough AJ, Feldstein AE. (2007)
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future.
Hepatology. 2007 Aug;46(2):582‑9.

Reply: Wieckowska A, McCullough AJ, Feldstein AE. (2007)
Hepatology. 2007 Dec;46(6):2047-8.

Yagmur E, Trautwein C, Leers MP, Gressner AM, Tacke F. (2007)
Elevated apoptosis‑associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation.
Clin Biochem. 2007 Jan 17;40(9-10):651-5.  

Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. (2007)
Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.
World J Gastroenterol. 2007 Feb 14;13(6):837‑44.

2006

Volkmann X, Cornberg M, Wedemeyer H, Lehner F, Manns MP, Schulze‑Osthoff K, Bantel H. (2006)
Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection.

Hepatology. 2006 Jun;43(6):1311‑6.

Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. (2006)
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.
Hepatology. 2006 Jul;44(1):27‑33.

2005

Kronenberger B, Wagner M, Herrmann E, Mihm U, Piiper A, Sarrazin C, Zeuzem S. (2005)
Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. 
J Viral Hepat. 2005 May;12(3):307‑14.

Seidel N, Volkmann X, Langer F, Flemming P, Manns MP, Schulze‑Osthoff K, Bantel H. (2005)
The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum.
Hepatology. 2005 Jul;42(1):113‑20.

2004

Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, Manns MP, Schulze‑Osthoff K. (2004)
Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury.
Hepatology. 2004 Nov;40(5):1078‑87.

Ramskogler K, Brunner M, Hertling I, Dvorak A, Kapusta N, Krenn C, Moser B, Roth G, Lesch OM, Ankersmit HJ, Walter H. (2004)
CDT values are not influenced by epithelial cell apoptosis in chronic alcoholic patients‑preliminary results.
Alcohol Clin Exp Res. 2004 Sep;28(9):1396‑8.

download this page as a .pdf